Letter regarding: Hepatitis B core-related antigen dynamics and risk of subsequent clinical relapses after nucleos(t)ide analog cessation
Clin Mol Hepatol. 2024 Jan 31. doi: 10.3350/cmh.2024.0064. Online ahead of print.NO ABSTRACTPMID:38295765 | DOI:10.3350/cmh.2024.0064 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 31, 2024 Category: Gastroenterology Authors: Yun-Fan Liaw Source Type: research
Global incidence of adverse clinical events in non-alcoholic fatty liver disease: A systematic review and meta-analysis
CONCLUSIONS: People with NAFLD have high incidence of liver and non-liver adverse clinical events, varying by NASH, geographic region, and time-period, but not sex.PMID:38281814 | DOI:10.3350/cmh.2023.0485 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 28, 2024 Category: Gastroenterology Authors: Michael H Le David M Le Thomas C Baez Hansen Dang Vy H Nguyen KeeSeok Lee Christopher D Stave Takanori Ito Yuankai Wu Yee Hui Yeo Fanpu Ji Ramsey Cheung Mindie H Nguyen Source Type: research
Identification of signature gene set as highly accurate determination of MASLD progression
CONCLUSIONS: We identified a signature gene set (i.e., CAPG, HYAL3, WIPI1, TREM2, SPP1, and RNASE6) with strong potential as a panel of diagnostic genes of MASLD-associated disease.PMID:38281815 | DOI:10.3350/cmh.2023.0449 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 28, 2024 Category: Gastroenterology Authors: Sumin Oh Yang-Hyun Baek Sungju Jung Sumin Yoon Byeonggeun Kang Su-Hyang Han Gaeul Park Je Yeong Ko Sang-Young Han Jin-Sook Jeong Jin-Han Cho Young-Hoon Roh Sung-Wook Lee Gi-Bok Choi Yong Sun Lee Won Kim Rho Hyun Seong Jong Hoon Park Yeon-Su Lee Kyung Hyun Source Type: research
Prognosis of biopsy-confirmed MASLD: a sub-analysis of the CLIONE study
CONCLUSIONS: Approximately 99% of NAFLD cases corresponded to MASLD. NAFLD only group, which is not included in MASLD, had relatively mild histopathologic severity and a favorable prognosis. Consequently, the prognosis of MASLD was similar to that of NAFLD.PMID:38263684 | DOI:10.3350/cmh.2023.0515 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 24, 2024 Category: Gastroenterology Authors: Michihiro Iwaki Hideki Fujii Hideki Hayashi Hidenori Toyoda Satoshi Oeda Hideyuki Hyogo Miwa Kawanaka Asahiro Morishita Kensuke Munekage Kazuhito Kawata Tsubasa Tsutsumi Koji Sawada Tatsuji Maeshiro Hiroshi Tobita Yuichi Yoshida Masafumi Naito Asuka Araki Source Type: research
Changing from NAFLD to MASLD: Similar Prognosis of Patients with HCC Under Atezo/Bev treatment between NAFLD and MASLD
Clin Mol Hepatol. 2024 Jan 18. doi: 10.3350/cmh.2023.0557. Online ahead of print.NO ABSTRACTPMID:38246698 | DOI:10.3350/cmh.2023.0557 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 21, 2024 Category: Gastroenterology Authors: Hiroyuki Suzuki Shigeo Shimose Hideki Iwamoto Takashi Niizeki Takumi Kawaguchi Source Type: research
Artificial intelligence predicts direct-acting antivirals failure among hepatitis C virus patients: A nationwide hepatitis C virus registry program
CONCLUSION: Machine learning algorithms effectively provide risk stratification for DAA failure and additional information on the factors associated with DAA failure.PMID:38195113 | PMC:PMC10776298 | DOI:10.3350/cmh.2023.0287 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 9, 2024 Category: Gastroenterology Authors: Ming-Ying Lu Chung-Feng Huang Chao-Hung Hung Chi-Ming Tai Lein-Ray Mo Hsing-Tao Kuo Kuo-Chih Tseng Ching-Chu Lo Ming-Jong Bair Szu-Jen Wang Jee-Fu Huang Ming-Lun Yeh Chun-Ting Chen Ming-Chang Tsai Chien-Wei Huang Pei-Lun Lee Tzeng-Hue Yang Yi-Hsiang Huang Source Type: research
JCAD Deficiency Attenuates Activation of Hepatic Stellate Cells and Cholestatic Fibrosis
CONCLUSION: JCAD deficiency effectively suppressed hepatic fibrosis induced by BDL in mice, and the underlying mechanisms are largely through suppressed Hippo-YAP signaling activity in HSCs.PMID:38190829 | DOI:10.3350/cmh.2023.0506 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 8, 2024 Category: Gastroenterology Authors: Li Xie Hui Chen Li Zhang Yue Ma Yuan Zhou Yong-Yu Yang Chang Liu Yu-Li Wang Ya-Jun Yan Jia Ding Xiao Teng Qiang Yang Xiu-Ping Liu Jian Wu Source Type: research
Efficacy, safety and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
CONCLUSIONS: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.PMID:38190830 | DOI:10.3350/cmh.2023.0422 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 8, 2024 Category: Gastroenterology Authors: Jinlin Hou Edward Gane Rozalina Balabanska Wenhong Zhang Jiming Zhang Tien Huey Lim Qing Xie Chau-Ting Yeh Sheng-Shun Yang Xieer Liang Piyawat Komolmit Apinya Leerapun Zenghui Xue Ethan Chen Yuchen Zhang Qiaoqiao Xie Ting-Tsung Chang Tsung-Hui Hu Seng Gee Source Type: research
JCAD Deficiency Attenuates Activation of Hepatic Stellate Cells and Cholestatic Fibrosis
CONCLUSION: JCAD deficiency effectively suppressed hepatic fibrosis induced by BDL in mice, and the underlying mechanisms are largely through suppressed Hippo-YAP signaling activity in HSCs.PMID:38190829 | DOI:10.3350/cmh.2023.0506 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 8, 2024 Category: Gastroenterology Authors: Li Xie Hui Chen Li Zhang Yue Ma Yuan Zhou Yong-Yu Yang Chang Liu Yu-Li Wang Ya-Jun Yan Jia Ding Xiao Teng Qiang Yang Xiu-Ping Liu Jian Wu Source Type: research
Efficacy, safety and pharmacokinetics of capsid assembly modulator linvencorvir plus standard of care in chronic hepatitis B patients
CONCLUSIONS: 48-week linvencorvir plus SoC was generally safe and well tolerated, and resulted in potent HBV DNA and RNA suppression. However, 48-week linvencorvir plus NUC with or without Peg-IFN did not result in the achievement of functional cure in any patient.PMID:38190830 | DOI:10.3350/cmh.2023.0422 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 8, 2024 Category: Gastroenterology Authors: Jinlin Hou Edward Gane Rozalina Balabanska Wenhong Zhang Jiming Zhang Tien Huey Lim Qing Xie Chau-Ting Yeh Sheng-Shun Yang Xieer Liang Piyawat Komolmit Apinya Leerapun Zenghui Xue Ethan Chen Yuchen Zhang Qiaoqiao Xie Ting-Tsung Chang Tsung-Hui Hu Seng Gee Source Type: research
Comprehensive Approach to Controlling Chronic Hepatitis B in China
Clin Mol Hepatol. 2024 Jan 5. doi: 10.3350/cmh.2023.0412. Online ahead of print.ABSTRACTHepatitis B virus (HBV) infection was highly endemic in China, where the prevalence of HBsAg was 9.7% in 1992. Comprehensive strategies, including universal infant hepatitis B vaccination with emphasis on timely birth-dose and 3-dose coverage, dramatically reduced the mother-to-infant transmission and early childhood acquisition of HBV, resulting in estimated HBsAg prevalence rates of 5.6% and 0.1% in the general population and among children aged <5 years in 2022, respectively. Clinical guidelines on the prevention and treatment of ...
Source: Clinical and molecular hepatology - January 4, 2024 Category: Gastroenterology Authors: Shan Shan Xinyan Zhao Jidong Jia Source Type: research
Evaluating the Therapeutic Efficacy of NAD Supplementation in Management of MASLD: Key Considerations
Clin Mol Hepatol. 2023 Dec 29. doi: 10.3350/cmh.2023.0555. Online ahead of print.NO ABSTRACTPMID:38163440 | DOI:10.3350/cmh.2023.0555 (Source: Clinical and molecular hepatology)
Source: Clinical and molecular hepatology - January 1, 2024 Category: Gastroenterology Authors: Xinyi Lu Rui Yang Yu Chen Daozhen Chen Source Type: research
